CN102552344B - Ramie plant extract, pharmaceutical composition containing the same and use thereof in improving liver function and treating liver diseases - Google Patents
Ramie plant extract, pharmaceutical composition containing the same and use thereof in improving liver function and treating liver diseases Download PDFInfo
- Publication number
- CN102552344B CN102552344B CN201110427884.5A CN201110427884A CN102552344B CN 102552344 B CN102552344 B CN 102552344B CN 201110427884 A CN201110427884 A CN 201110427884A CN 102552344 B CN102552344 B CN 102552344B
- Authority
- CN
- China
- Prior art keywords
- boehmeria
- section
- plant
- genus
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003908 liver function Effects 0.000 title claims abstract description 14
- 240000008564 Boehmeria nivea Species 0.000 title claims description 13
- 208000019423 liver disease Diseases 0.000 title abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000000419 plant extract Substances 0.000 title 1
- 241001649247 Boehmeria Species 0.000 claims abstract description 83
- 235000013402 health food Nutrition 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 33
- 238000000605 extraction Methods 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 14
- 239000012567 medical material Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000004615 ingredient Substances 0.000 claims description 8
- 238000004587 chromatography analysis Methods 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000005516 engineering process Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 abstract description 6
- 210000005228 liver tissue Anatomy 0.000 abstract 2
- 230000017423 tissue regeneration Effects 0.000 abstract 2
- 230000001737 promoting effect Effects 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 38
- 239000008280 blood Substances 0.000 description 38
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 28
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 28
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 27
- 108010082126 Alanine transaminase Proteins 0.000 description 27
- 108090000340 Transaminases Proteins 0.000 description 26
- 238000002347 injection Methods 0.000 description 26
- 239000007924 injection Substances 0.000 description 26
- 102000014898 transaminase activity proteins Human genes 0.000 description 26
- 239000000243 solution Substances 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 21
- 238000004108 freeze drying Methods 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 18
- 238000000034 method Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 208000019425 cirrhosis of liver Diseases 0.000 description 12
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 238000010171 animal model Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 8
- 238000005266 casting Methods 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000002440 hepatic effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 5
- 208000030090 Acute Disease Diseases 0.000 description 4
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 description 4
- 241000218215 Urticaceae Species 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 description 4
- 229960004245 silymarin Drugs 0.000 description 4
- 235000017700 silymarin Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000218922 Magnoliophyta Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 208000018191 liver inflammation Diseases 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 238000004816 paper chromatography Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- -1 phenol compound Chemical class 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- YZAZXIUFBCPZGB-QZOPMXJLSA-N (z)-octadec-9-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O YZAZXIUFBCPZGB-QZOPMXJLSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241001528009 Boehmeria biloba Species 0.000 description 1
- 241001361636 Boehmeria boninensis Species 0.000 description 1
- 241000068289 Boehmeria cylindrica Species 0.000 description 1
- 241001456086 Boehmeria grandis Species 0.000 description 1
- 241000708387 Boehmeria platanifolia Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- HTRXGEPDTFSKLI-UHFFFAOYSA-N butanoic acid;ethyl acetate Chemical compound CCCC(O)=O.CCOC(C)=O HTRXGEPDTFSKLI-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N chcl3 chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000003049 inorganic solvent Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000003161 proteinsynthetic effect Effects 0.000 description 1
- NHDHVHZZCFYRSB-UHFFFAOYSA-N pyriproxyfen Chemical compound C=1C=CC=NC=1OC(C)COC(C=C1)=CC=C1OC1=CC=CC=C1 NHDHVHZZCFYRSB-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 210000001171 synovial bursa Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a pharmaceutical composition and/or health food prepared from plants of the genus Boehmeria (Boehmeria species). The pharmaceutical composition and/or health food can be used for improving liver function and treating liver diseases, and promoting liver tissue regeneration (liver tissue regeneration).
Description
[technical field]
The present invention relates to a kind of medical composition, particularly relate to a kind of medical composition of the extract that contains Section of Genus Boehmeria plant (Boehmeria species), it shows the effect of height in improving liver function.
[prior art]
Liver is vitals, and it is playing the part of important role in disintegrating or modifying the metabolism of noxious substance.Liver is also carried out other critical function, and for example hepatic glycogen stores (glycogen storage), hormone manufacture, plasma protein synthetic (plasma protein synthesis) decomposes with red blood cell.
Life-threatening hepatic disease comprises liver cirrhosis (liver cirrhosis), liver viral infection and hepatocarcinoma, and these diseases originate in inflammation (liver inflammation) and/or hepatic fibrosis (liver fibrosis).
At present there is not suitable can be used to treat the medicine of these hepatic disease, therefore, aspect enhancing liver function and treatment hepatic disease, there are eager needs.
[summary of the invention]
The invention provides a kind of medical composition, it is prepared by extraction process, and this extraction process comprises: soak the some of Section of Genus Boehmeria plant (Boehmeria species) in water; Remove this part of this Section of Genus Boehmeria plant to obtain solution; And concentrate this solution so that medical composition to be provided, wherein this Section of Genus Boehmeria plant is the unique medical material in this extraction process.
The present invention also provides a kind of medical composition for the treatment of hepatic disease, comprises extract and pharmaceutically acceptable carrier as the Section of Genus Boehmeria plant of active ingredient.
The extract that the present invention more provides a kind of Section of Genus Boehmeria plant is in the purposes for the preparation of improving in the health food of liver function, and wherein the extract of this Section of Genus Boehmeria plant is prepared by extraction process, comprising: soak the some of Section of Genus Boehmeria plant in water; Remove this part of this Section of Genus Boehmeria plant to obtain solution; And concentrate this solution so that extract to be provided, wherein this Section of Genus Boehmeria plant is the unique medical material in this extraction process.
The purposes of the extract that the present invention separately provides a kind of Section of Genus Boehmeria plant in the medicine for the preparation for the treatment of hepatic disease, wherein the extract of this Section of Genus Boehmeria plant is prepared by extraction process, comprising: soak the some of Section of Genus Boehmeria plant in water; Remove this part of this Section of Genus Boehmeria plant to obtain solution; And concentrate this solution so that extract to be provided, wherein this Section of Genus Boehmeria plant is the unique medical material in this extraction process.
For above and other objects of the present invention, feature and advantage can be become apparent, preferred embodiment cited below particularly, and coordinate accompanying drawing, be described in detail below.
[accompanying drawing explanation]
Figure 1A display analysis is taken from matched group and is respectively processed the result of the aspartic transaminase in the blood sample of animal of group.
Figure 1B display analysis is taken from matched group and is respectively processed the result of the alanine aminotransferase in the blood sample of animal of group.
Fig. 1 C shows and to take from matched group and respectively to process aspartic transaminase in the blood sample of animal of group and the ratio of alanine aminotransferase.
Fig. 2 shows the mark result of calculation of the degree of hepatic fibrosis of respectively testing group.
Fig. 3 A shows group (1) lumbar injection 300mg/kg thioacetamide and the oral 300mg/kg of casting BL-01-01 (solution) and group (2) 300mg/kg thioacetamide and the oral activity that casts the aspartic transaminase of 300mg/kg BL-01-01 (through lyophilization).
Fig. 3 B shows group (3) lumbar injection 300mg/kg thioacetamide and the oral activity that casts the aspartic transaminase of 500mg/kg BL-02 (through lyophilization).
Fig. 3 C shows group (1) lumbar injection 300mg/kg thioacetamide and the oral 300mg/kg of casting BL-01-01 (solution) and group (2) lumbar injection 300mg/kg thioacetamide and the oral activity that casts the alanine aminotransferase of 300mg/kg BL-01-01 (through lyophilization).
Fig. 3 D shows group (3) lumbar injection 300mg/kg thioacetamide and the oral activity that casts the alanine aminotransferase of 500mg/kg BL-02 (through lyophilization).
Fig. 3 E demonstration group (1) lumbar injection 300mg/kg thioacetamide and the oral 300mg/kg of casting BL-01-01 (solution) and group (2) lumbar injection 300mg/kg thioacetamide and the oral aspartic transaminase that casts 300mg/kg BL-01-01 (through lyophilization) are than the ratio of alanine aminotransferase.
Fig. 3 F shows that group (3) lumbar injection 300mg/kg thioacetamide and the oral aspartic transaminase that casts 500mg/kg BL-02 (through lyophilization) are than the ratio of alanine aminotransferase.
[specific embodiment]
In a specific embodiments of the present invention, the invention provides a kind of medical composition, and this medical composition comprises the extract of Section of Genus Boehmeria (Boehmeria) plant.
Section of Genus Boehmeria is that one in Urticaceae (nettle family) Urticaceae belongs to (genus), and its in Urticaceae approximately 100 kinds (species) former flowering plant (flowering plant) that is born in Asia and North America forms.The plant that belongs to Section of Genus Boehmeria comprises, for example, sieve yarn fiber crops (Boehmeria biloba), the former Boehmeria of little large bamboo hat with a conical crown and broad brim (Boehmeria boninensis), cylinder flower Boehmeria (Boehmeria cylindrica), mountain Boehmeria (Boehmeria nivea L.var. tenacissima), Flos Caryophylli Boehmeria (Boehmeria grandis), Jamaica Boehmeria (Boehmeria jamaicensis), Boehmeria (Boehmeria nivea L.Gaud.) and Herba Boehmeriae platyphllae (Boehmeria platanifolia).
In one embodiment of the invention, with aqueous solution, the root of Section of Genus Boehmeria (Boehmeria) plant, stem, leaf or flower are carried out extraction process and prepared medical composition of the present invention.In one embodiment, Section of Genus Boehmeria plant can comprise any Section of Genus Boehmeria plant, is preferably Boehmeria (Boehmeria nivea L.Gaud.) or mountain Boehmeria (Boehmeria nivea L.var.tenacissima).In yet another embodiment, Section of Genus Boehmeria plant is medical material unique in above-mentioned extraction process.
Above-mentioned extraction process can comprise step as described below, but is not limited to this.
First, the dry root of Boehmeria is soaked in the water of 20-70 ℃ (being preferably 25-40 ℃).In one embodiment, water can be cold water (in the water of room temperature), and the cold water extract of Section of Genus Boehmeria plant demonstrates the effect of height in improving liver function.The glassware for drinking water using has 90% or higher purity.It can comprise on a small quantity the organic solvent of (that is, < 10%), for example methanol, ethanol, acetone and acetonitrile.
And according to adopted extraction conditions, the time of immersion can be variation, extraction conditions can comprise, such as used extractant, extraction temperature etc., but be not limited to this.In one embodiment, the time of immersion can be 2 hours to 7 days.
Then,, after soaking, the root of plant is removed and solvent is concentrated so that thick extraction product to be provided.Can rinse (rinse) to remove specific impurities by slightly extracting thing.For example, first will slightly extract product is dissolved in polar solvent, for example ethanol, water or its mixture, afterwards by produced solution with non-polar solven, for example normal hexane rinses to remove lipid or other apolar substance, or rinses to remove little phenolic compound (small phenol compound) with chloroform (chloroform) or ethyl acetate (ethyl acetate).Finally, the solution through rinsing is concentrated into and is dried so that the product through part purification to be provided.
In addition, also can be increased in and improve the effective ingredient that liver function aspect demonstrates effect with chromatographic technique.Chromatographic technique comprises paper chromatography technology (paper chromatography), TLC technique (thin layer chromatography), column chromatography technology, gas chromatographic technique (gas chromatography) and liquid chromatography technology (liquid chromatography) (for example, high-efficient liquid phase chromatogram technology).Applicable eluent solvent includes, but are not limited to water, methanol (CH
3oH), acetonitrile (CH
3cN) with its mixture.Can use gradient elution system (gradient eluent system).Or, also can use recrystallization (recrystallization) to increase the effective ingredient of one or more.The solvent of recrystallization can be inorganic or organic solvent, and for example, required product has low solubility at low temperatures therein, but at high temperature has the solvent of high-dissolvability.It also can be solvent to (solvent pair) or mixture.Can therefore obtain the product of purification more.
By using chromatographic technique or Other Instruments, for example UV or NMR can measure structure and the purity thereof of effective ingredient.
In one embodiment, the temperature that the product therefore obtaining can be stored in to room temperature (ambient temperature) or reduce, and can be stored in protective gas, for example, under nitrogen, argon or helium.
Above-mentioned obtained the pharmaceutically effective prepared product of useful effective dose improves liver function, treatment hepatic fibrosis, liver cirrhosis, liver is acute or chronic inflammatory disease, liver infection and hepatocarcinoma, and makes impaired liver organization regeneration.
Wording " is improved liver function " and is referred to, no matter above-mentioned prepared product is cast to the individuality whether with hepatic disease, to strengthen, metabolism, the hepatic glycogen of its liver stores, red blood cell decomposes, plasma proteins is synthetic, the ability of hormone manufacture or toxin expelling (detoxification).
Wording " treatment hepatic disease " refers to, by above-mentioned prepared product cast to thering is hepatic fibrosis, liver cirrhosis, liver is acute or chronic inflammatory disease, liver viral infection (for example, Type B or hepatitis C virus infect) or the disease of hepatocarcinoma, or there is the symptom of this disease, or there is the individuality of the body constitution that this disease is easily caught an illness, based on eliminating, cure, alleviate, relax, change, treat, improve, improve or affect the symptom of this disease, this disease, the object of body constitution that this disease is easily caught an illness.
Wording " make liver organization regeneration " refers to, above-mentioned prepared product is cast to its liver because of disease, ethanol, medicine or other former thereby impaired individuality, makes liver injury reverse to promote the regeneration of liver organization.
Wording " effective dose " refers to, gives the amount of this required prepared product of one of individual above-mentioned effect.And the judgement of using according to the kind of effect, route of administration, excipient and using altogether the probability of (co-usage) to carry out with other treatment due to person skilled in the art, effective dose presents variation.
In order to implement method of the present invention, can be by the compositions of the above-mentioned polymerizable compound that comprises one or more (polymeric compounds), in the mode of parenteral (parenterally), oral (orally), per nasal (nasally), per rectum (rectally), local (topically) or mouthful cheek (buccally), cast.Wording " parenteral " in this use refers to, (intrasynovial), breastbone interior (intrasternal), sheath interior (intrathecal), disease location interior (intraleaional) or intracranial (intracranial) injection and any applicable infusion techniques (infusion technique) in subcutaneous (subcutaneous), Intradermal (intracutaneous), intravenous (intravenous), intramuscular (intramuscular), intraarticular (intraarticular), intra-arterial (intraarterial), synovial bursa (chamber).
Aseptic injection compositions (sterile injectable composition) can be solution or the suspension in the parenteral acceptable diluent of avirulence (diluent) or solvent, for example, 1, solution in 3-butanediol (1,3-butane diol).Spendable acceptable mediator (vehicle) comprises mannitol (mannitol) and water with solvent.In addition, expressed oi (fixed oil) is often used as solvent or suspension media (suspending medium) (for example, synthetic list-or double glyceride (mono-or diglycerides)).Fatty acid, for example oleic acid (oleic acid) and its glyceride (glyceride) derivant also can be used for the preparation of injection, it is acceptable oil in natural medicaments, for example olive oil, Oleum Ricini (castor oil), particularly in its polyoxy ethylating (polyoxyethylated) version.These oil solutions or suspension also can comprise long-chain alcohols diluent or dispersant (dispersant), or carboxymethyl cellulose (carboxymethyl cellulose) or similar dispersant.Other normally used surfactant (surfactant), for example Tweens (Tweens) or spans (Spans) or other similar emulsifying agent (emulsifying agent) or bioavailability reinforcing agent (bioavailability enhancer), it is used in the manufacture of pharmaceutically acceptable solid, liquid or other dosage form (dosage form) conventionally, also can be used for the object of preparation.
Compositions for oral administration can be any oral acceptable dosage form, comprises capsule, lozenge, Emulsion (emulsions), waterborne suspension (aqueous suspensions), dispersion liquid (dispersions) and solution.As for lozenge, its common used carrier (carrier) comprises lactose and corn starch.Generally also add lubricant (lubricating agent), for example magnesium stearate (magnesium stearate).For the oral administration with capsule form, useful diluent comprises the corn starch of lactose and drying.When waterborne suspension or Emulsion are oral administration, effective ingredient (active ingredient) can be suspended or be dissolved in oil phase (oily phase) that emulsifying or suspending agent are combined.If need, can add specific sweet taste, seasoning and coloring agent.
According to the known technology in medical formulation art, can prepare nose aerosol (aerosol) or inhalant (inhalation) compositions.For example, the absorption enhancer, fluorocarbon (fluorocarbon) and/or other other hydrotropy or the dispersant of knowing in the art that utilize benzyl alcohol (benzyl alcohol) or other applicable antiseptic, enhancing bioavailability (bioavailability), can be prepared into this kind of compositions saline solution (solution in saline).For the administration of per rectum mode, there is the form that the compositions of the active compound of one or more also can suppository (suppository) and give.
Carrier in medical composition must be " acceptable ", itself and the effective ingredient of filling a prescription compatible (and being preferably the ability with stable effective ingredient), and harmful to the individuality that will be treated.The cosolvent of one or more for sending of effective ingredient as the accessory drugs on pharmacology.The example of other carrier comprises silica sol (colloidal silicon dioxide), magnesium stearate, cellulose, alkyl sulfate (for example sodium lauryl sulfate, sodium lauryl sulfate) and D & C Yellow #10.
Effect that can test compounds by external or body inner analysis.For example, can Preliminary screening compound of the present invention by analyzed in vitro, and in analyzing in vitro, just about the biological activity of the compound of liver function, test.By method in the known body of the art, can further be evaluated in Preliminary screening and show the compound with high effect, for example to assess them, in treatment hepatic disease, the activity of liver cancer.
In another specific embodiments of the present invention, the present invention also provides a kind of medical composition for the treatment of hepatic disease.The medical composition of this treatment hepatic disease can comprise extract and the pharmaceutically acceptable carrier as the Section of Genus Boehmeria plant of active ingredient.In one embodiment, the extract of Section of Genus Boehmeria plant is water extraction thing.
Above-mentioned hepatic disease can include, but are not limited to liver acute or chronic inflammatory disease (acute or chronic liver inflammation), hepatic fibrosis (liver fibrosis) and/or liver cirrhosis (liver cirrhosis).
And in another specific embodiments of the present invention, the extract that the invention provides a kind of Section of Genus Boehmeria plant is in the purposes for the preparation of improving in the health food of liver function.In one embodiment, the extract in the Section of Genus Boehmeria plant described in this can obtain by above-mentioned extraction process.In one embodiment, in the Section of Genus Boehmeria plant described in this, any Section of Genus Boehmeria plant be can comprise, Boehmeria (Boehmeria nivea L.Gaud.) or mountain Boehmeria (Boehmeria nivea L.var.tenacissima) are preferably.In yet another embodiment, Section of Genus Boehmeria plant is medical material unique in above-mentioned extraction process.
In addition, in another specific embodiments again of the present invention, the purposes of the extract that the invention provides a kind of Section of Genus Boehmeria plant in the medicine for the preparation for the treatment of hepatic disease.In one embodiment, the extract in the Section of Genus Boehmeria plant described in this can obtain by above-mentioned extraction process.In one embodiment, in the Section of Genus Boehmeria plant described in this, any Section of Genus Boehmeria plant be can comprise, Boehmeria (Boehmeria nivea L.Gaud.) or mountain Boehmeria (Boehmeria nivea L.var.tenacissima) are preferably.In yet another embodiment, Section of Genus Boehmeria plant is medical material unique in above-mentioned extraction process.
Above-mentioned hepatic disease can include, but are not limited to hepatic fibrosis, liver cirrhosis, liver is acute or chronic inflammatory disease, hepatitis virus B infection, hepatitis C virus infection or hepatocarcinoma.
[embodiment]
1. the preparation of plant-based medicine extract (botanical extract)
The root (2.5kg) of Boehmeria (Boehmeria nivea L.Gaud.) is soaked in water (50L) in room temperature is overnight.After root is removed, aqueous solution is concentrated into the mixture containing 20% solids content (the solid content) that have an appointment, to produce the extract product B L-01-01 (through concentrated solution) of 682g, it is containing the solids content of 20% weight of having an appointment.The some of the extract solution through concentrated is carried out to lyophilization to produce dry solid product.
By separated root overnight being soaked in water (50L) again, afterwards water is removed, and repeat after this process secondary, root refluxed in water (reflux) 5 hours and be cooled to afterwards room temperature.After shifting out from water, root is refluxed 4 hours in the same way again.The extractant of reflux course is for the second time carried out to lyophilization and can obtain the extract product (BL-01-12) that 96g is dry.
The root (20g) of Boehmeria (Boehmeria nivea L.Gaud.) is refluxed 5 hours in water (400mL), and be cooled to afterwards room temperature.After root is removed, extractant is carried out to lyophilization so that the extract product (BL-02) of 3.17g to be provided.
2. bioanalysis
2.1 experiment materials and method
Laboratory animal is that male Si Pula-Dao carrys out (Sprague Dawely) rat.Basic reference material and data that this strain laboratory animal is existing abundant, applicable to by carbon tetrachloride (CCl
4) the Hepatic Fibrosis of Animal model of inducing.Experimental animal feeding is the light-dark cycle (light-dark cycle) of 12 hours in the automatic control of light application time, and temperature is controlled at 23 ± 2 ℃, and humidity is controlled at the room of 40-70%.And allow rat freely to take food and water.
The rat in 8 week age is used in test.Experimental session carries out clinical observation every day, and carries out record for abnormal symptom and dead laboratory animal, and dissects to assess reason.
Except matched group is 3 laboratory animals and does not do any processing, all the other laboratory animals are divided into 6 and process group, and each is tested group and comprises 8 laboratory animals, and with intraperitoneal (intraperitoneally), injects the CCl of 0.4ml/kg
4(for example, 1.67ml/kg, 24% CCl
4be dissolved in olive oil) biweekly.Also by raising by force (gavage) mode every day, with one of following casting, respectively process group and reach 8 weeks: (1) solvent, (2) silymarin (silymarin) 200mg/kg, (3) BL-01-12 100mg/kg, (4) BL-01-12 300mg/kg, (5) BL-01-12 900mg/kg, and (6) BL-01-01 300mg/kg.
At CCl
4before injection with after injection once every two weeks until the 8th week, from the afterbody extraction blood sample of matched group and processed group animal.By blood sample be maintained at room temperature 1 hour and 25 ℃ with centrifugal 10 minutes of 6000rpm to obtain serum.With dry type biochemistry analyzer (Kodak Ektachem DT60II), analyze the activity of alanine aminotransferase (alanine aminotransferase, ALT) and aspartic transaminase (aspartate aminotransferase, AST).It should be noted that the pointer that alanine aminotransferase and the aspartic transaminase degree in blood is liver function.Referring to, Clinical Laboratory Medicine, Ed.by Kenneth McClatchey, Lippincott Williams & Wilkins, 2002, page 288.
When within the 8th week, finishing, the animal of all matched groups and processed group is put to death.The lobus sinister of the liver from each animal is fixed in 3.7% formalin (formalin) solution.Tissue through fixing is dewatered with the order of following 30,50,70,95,99.5% ethanol and dimethylbenzene (xylene), until bleach.Dimethylbenzene is replaced with paraffin (paraffin).Paraffin embedding sample is cut into 5 μ m slabs, and its section is placed on a glass slide and in 37 ℃ and is dried to carry out following Picro-Sirius red and fast green dyeing (Sirius red & Fast green staining) and carries out collagen protein (collagen) dyeing.
Liver section is processed three times with dimethylbenzene, each 3 minutes, to remove paraffin, and afterwards by its order rehydration with following 100,100,90,70,50% ethanol and TBST (each 3 minutes).Afterwards, the section through rehydration is dyeed 1 hour with 0.1% fast green (Fast green) with 0.1% Picro-Sirius red (Sirius red).After dyeing, the process that slide is carried out to another dehydration with the order (each 10 seconds) of following 50,70,90,100 and 100% ethanol and dimethylbenzene.They are further processed three times and bleach with dimethylbenzene.For ensuing hepatic fibrosis assessment, transparent, dyed liver section is fixed with colloid and stored.
Section through fixing is checked and taken a picture under Olympus DT70-BX51 microscope.According to 5 of Metavir marking system kinds of grades, can assess hepatic fibrosis: (F0) without fibrosis, (F1) (portal) fibrosis of hepatic portal is without barrier film (septa), (F2) fibrosis of hepatic portal has minority barrier film, (F3) numerous barrier film is without liver cirrhosis (cirrhosis), (F4) liver cirrhosis, as at Boigk et al., Hepatology, 1997,26:643-649 and Ruwart et al., Hepatology, described in 1989,10:801-806.
Use student ' s t-to check to measure significance.Statistical significance is used in P value < 0.05.
2.2 result
For taking from matched group and with (1) solvent, (2) silymarin (silymarin) 200mg/kg, (3) BL-01-12 100mg/kg, (4) BL-01-12 300mg/kg, (5) BL-01-12 900mg/kg, analyzes the value of aspartic transaminase and alanine aminotransferase with the blood sample of other animal of (6) BL-01-01 300mg/kg processed group.Result is as shown in Figure 1A, 1B and 1C.
First, referring to Figure 1A, its display analysis is taken from the result of the aspartic transaminase in matched group and the above-mentioned blood sample of respectively processing group animal.Than the 2nd week, the blood sample of group (2)-(5), it had a large amount of liftings in the time of the 4th week aspect meansigma methods of aspartic transaminase, but did not observe this kind of variation in the blood sample of group (1) and (6).In the time of the 6th week, blood sample than group (1), average aspartic transaminase value in the blood sample of group (5) and (6) reduces significantly, and in the blood sample of group (4), its average aspartic transaminase value lower than the blood sample of group (3) quite many, average aspartic transaminase value in the blood sample of group (3) again, it is the average aspartic transaminase value with the blood sample of (2) lower than group (1) significantly.In the time of the 8th week, the average aspartic transaminase value in all treated samples is reduced to close to the normal value in matched group sample.
Referring to Figure 1B, its display analysis is taken from matched group and is respectively processed the result of the alanine aminotransferase in the blood sample of group animal.Than the 2nd week, the blood sample of group (2), (4) and (5), it had a large amount of liftings in the time of the 4th week aspect meansigma methods of alanine aminotransferase, but did not observe this kind of variation in the blood sample of group (1), (3) and (6).In the time of the 6th week, blood sample than group (1), average alanine aminotransferase value in the blood sample of group (6) reduces significantly, and in the blood sample of group (4) and (5), average alanine aminotransferase value lower than the blood sample of group (3) quite many, and average alanine aminotransferase value in the blood sample of group (3), it is the average alanine aminotransferase value with the blood sample of (2) lower than group (1) significantly.Than the 6th week, in the time of the 8th week, from the average alanine aminotransferase value reduction of treated blood sample, it was close to the normal value in matched group sample.
Moreover referring to Fig. 1 C, its demonstration is taken from matched group and is respectively processed aspartic transaminase in the blood sample of group animal and the ratio of alanine aminotransferase.Than the 2nd week, in the time of the 4th week, the blood sample of group (1)-(6), it has a large amount of attenuatings aspect aspartic transaminase/alanine aminotransferase ratio; In the blood sample of these 6 groups, the mean ratio in the blood sample of group (2), (4) and (5) is significantly lower than the blood sample in group (1) and the mean ratio in matched group sample.Than the 4th week, in the time of the 6th week, in the blood sample of group (4)-(6), mean ratio had a large amount of increases, and they are significantly higher than the mean ratio in the blood sample of group (1).Significantly higher aspartic transaminase/alanine aminotransferase ratio is pointed out, in the time of the 6th week, and the CCl in the animal of group (4)-(6)
4the inflammation of induction significantly reduces.
When finishing with the 6th week during than the 8th week among the mean ratio of lifting, only there is the blood sample of group (6) to there is the ratio of the blood sample of group of being significantly higher than (1).
When within the 8th week, finishing, the animal of all matched groups and processed group is put to death as previously mentioned.And the pathological examination of the liver organization obtaining when the experiment at 8 girths finishes according to this, to judge the degree of hepatic fibrosis of each group, and mark result of calculation is shown in Fig. 2.
As shown in Figure 2, the animal of group (6) has compared with the degree of hepatic fibrosis of the animal of group (1)-(5) the trend that obvious minimizing improves to result.The animal of group (6) is processed with test substances BL-01-01.Therefore, BL-01-01 is avoiding in hepatic fibrosis, demonstrating unforeseeable superior effect.
3. acute hepatic inflammatory model
The male sprague-Dawley rat of usining brings out the animal model of acute hepatic inflammation as test by thioacetamide (thioacetamide, TAA).After first 24 hours of rats by intraperitoneal injection thioacetamide and lumbar injection thioacetamide the 24th, 48 hours, in saphena blood sampling mode, gather about 0.3ml blood and using as the analysis of blood biochemical value.Each tests group, and details are as follows.
Rat is respectively with (1) lumbar injection 300mg/kg thioacetamide and the oral 300mg/kg BL-01-01 (solution) that casts, (2) lumbar injection 300mg/kg thioacetamide and the oral 300mg/kg BL-01-01 (through lyophilization) that casts, (3) lumbar injection 300mg/kg thioacetamide and the oral 500mg/kg of casting BL-02 (through lyophilization) process, and the blood sample analysis of rat are measured to the value of aspartic transaminase and alanine aminotransferase to be similar to above-mentioned method.Result is shown in Fig. 3 A to Fig. 3 F.
Fig. 3 A shows group (1) lumbar injection 300mg/kg thioacetamide and the oral 300mg/kg of casting BL-01-01 (solution) and group (2) lumbar injection 300mg/kg thioacetamide and the oral aspartic transaminase activity that casts 300mg/kg BL-01-01 (through lyophilization).Fig. 3 B shows group (3) lumbar injection 300mg/kg thioacetamide and the oral aspartic transaminase activity that casts 500mg/kg BL-02 (through lyophilization).3C figure shows group (1) lumbar injection 300mg/kg thioacetamide and the oral 300mg/kg of casting BL-01-01 (solution) and group (2) lumbar injection 300mg/kg thioacetamide and the oral alanine aminotransferase activity that casts 300mg/kg BL-01-01 (through lyophilization).Fig. 3 D shows group (3) lumbar injection 300mg/kg thioacetamide and the oral alanine aminotransferase activity that casts 500mg/kg BL-02 (through lyophilization).Fig. 3 E demonstration group (1) lumbar injection 300mg/kg thioacetamide and the oral 300mg/kgBL-01-01 of casting (solution) and group (2) lumbar injection 300mg/kg thioacetamide and the oral aspartic transaminase that casts 300mg/kg BL-01-01 (through lyophilization) are than the ratio of alanine aminotransferase.Fig. 3 F shows that group (3) lumbar injection 300mg/kg thioacetamide and the oral aspartic transaminase that casts 500mg/kg BL-02 (through lyophilization) are than the ratio of alanine aminotransferase.
Result shows, after thioacetamide is processed 24 and 48 hours, and BL-01-01 (through concentrated solution) significantly suppresses the value increase of aspartic transaminase; After thioacetamide is processed 24 and 48 hours, BL-01-01 (through lyophilization) significantly suppresses the increase of the value of alanine aminotransferase; And after thioacetamide is processed 24 and 48 hours, BL-02 (through lyophilization) there is no the value increase of remarkable inhibition aspartic transaminase or alanine aminotransferase.Therefore,, in treatment acute hepatic inflammation, BL-01-01 (solution) and BL-01-01 (through lyophilization) are better than BL-02 effect.
4. other embodiment
All features that this description can be disclosed are combined into any combination.Alternative features identical by having, equal or similar object can replace each feature being disclosed in this description.Therefore,, unless otherwise narration especially, each disclosed feature is only an embodiment of the universal serial of equal or similar features.
Although the present invention discloses as above with preferred embodiment; yet it is not in order to limit the present invention, anyly have the knack of this operator, without departing from the spirit and scope of the present invention; when doing a little change and modification, thus protection scope of the present invention when with claims the person of being defined be as the criterion.
Claims (9)
1. a medical composition, it is prepared by extraction process, and this extraction process system is consisted of the following step:
Soak the some of Section of Genus Boehmeria plant (Boehmeria species) in the water of room temperature;
Remove this part of this Section of Genus Boehmeria plant to obtain solution; And
Concentrate this solution so that medical composition to be provided,
Wherein this Section of Genus Boehmeria plant is the unique medical material in this extraction process.
2. medical composition as claimed in claim 1, wherein this Section of Genus Boehmeria plant is Boehmeria (Boehmeria nivea L.Gaud.) or mountain Boehmeria (Boehmeria nivea L.var.tenacissima).
3. medical composition as claimed in claim 1, wherein soak time is 2-24 hour.
4. medical composition as claimed in claim 1, wherein this medical composition also comprises the step that is increased in the effective ingredient in concentrated solution by chromatographic technique.
5. medical composition as claimed in claim 4, wherein this chromatographic technique is column chromatography technology or high-efficient liquid phase chromatogram technology.
6. medical composition as claimed in claim 5, the eluent being wherein used in this chromatographic technique comprises H
2o, CH
3cN, CH
3oH or its mixture.
7. the extract of Section of Genus Boehmeria plant is in the purposes for the preparation of improving in the health food of liver function, and wherein the extract of this Section of Genus Boehmeria plant is prepared by extraction process, and this extraction process system is consisted of the following step:
Soak the some of Section of Genus Boehmeria plant (Boehmeria species) in the water of room temperature;
Remove this part of this Section of Genus Boehmeria plant to obtain solution; And
Concentrate this solution so that extract to be provided,
Wherein this Section of Genus Boehmeria plant is the unique medical material in this extraction process.
The extract of Section of Genus Boehmeria plant for the preparation for the treatment of hepatic fibrosis medicine in a purposes, wherein the extract of this Section of Genus Boehmeria plant is prepared by extraction process, the following step, is consisted of:
Soak the some of Section of Genus Boehmeria plant (Boehmeria species) in the water of room temperature;
Remove this part of this Section of Genus Boehmeria plant to obtain solution; And
Concentrate this solution so that extract to be provided,
Wherein this Section of Genus Boehmeria plant is the unique medical material in this extraction process.
9. treat a medical composition for hepatic fibrosis, comprise that wherein the extract of this Section of Genus Boehmeria plant is prepared by extraction process, the following step, is consisted of as extract and the pharmaceutically acceptable carrier of the Section of Genus Boehmeria plant of active ingredient:
Soak the some of Section of Genus Boehmeria plant (Boehmeria species) in the water of room temperature;
Remove this part of this Section of Genus Boehmeria plant to obtain solution; And
Concentrate this solution so that extract to be provided,
Wherein this Section of Genus Boehmeria plant is the unique medical material in this extraction process.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/978,756 | 2010-12-27 | ||
| US12/978,756 US20120164241A1 (en) | 2010-12-27 | 2010-12-27 | Boehmeria extract and its use in treating liver diseases |
| TW100145288A TWI527587B (en) | 2010-12-27 | 2011-12-08 | Use of boehmeria species extract in manufacturing drug for treating liver fibrosis |
| TW100145288 | 2011-12-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102552344A CN102552344A (en) | 2012-07-11 |
| CN102552344B true CN102552344B (en) | 2014-04-16 |
Family
ID=46399802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110427884.5A Active CN102552344B (en) | 2010-12-27 | 2011-12-19 | Ramie plant extract, pharmaceutical composition containing the same and use thereof in improving liver function and treating liver diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102552344B (en) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100457127C (en) * | 2003-12-26 | 2009-02-04 | 财团法人工业技术研究院 | Medicinal herb solvent extract for treating hepatic disease |
| CN1290520C (en) * | 2003-12-31 | 2006-12-20 | 财团法人工业技术研究院 | Method for preparing hepatitis treating medicine and the product produced thereby |
| CN102429936A (en) * | 2010-09-29 | 2012-05-02 | 苏州瑞蓝博中药技术开发有限公司 | Method for purifying phenolic acid from ramie |
| CN101978976A (en) * | 2010-10-19 | 2011-02-23 | 南京泽朗医药科技有限公司 | Method for extracting and purifying total phenolic acid from fresh ramie leaves |
-
2011
- 2011-12-19 CN CN201110427884.5A patent/CN102552344B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN102552344A (en) | 2012-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104225524B (en) | Purposes of the snakegourd Guizhi decoction in the medicine for preparing treatment or/and prevention cognition dysfunction | |
| CN105232621A (en) | Processing method of fructus psoraleae medicinal materials, fructus psoraleae extract and pharmaceutical composition | |
| Das et al. | Evaluation of Anti–Inflammatory, Anti–diabetic activity of Indian Bauhinia vahlii (stembark) | |
| Mao et al. | Yunpi Heluo decoction attenuates insulin resistance by regulating SIRT1-FoxO1 autophagy pathway in skeletal muscle of Zucker diabetic fatty rats | |
| Zhao et al. | Meconopsis horridula Hook. f. & Thomson extract and its alkaloid oleracein E exert cardioprotective effects against acute myocardial ischaemic injury in mice | |
| Abebe et al. | Sub-chronic toxicity of ethanol leaf extract of Syzygium guineense on the biochemical parameters and histopathology of liver and kidney in the rats | |
| CN102552344B (en) | Ramie plant extract, pharmaceutical composition containing the same and use thereof in improving liver function and treating liver diseases | |
| CN104257811A (en) | Food, health product or pharmaceutical composition with effect of protecting liver | |
| US10137159B2 (en) | Boehmeria extract and its use in treating liver diseases | |
| CN113181177B (en) | Application of harmine derivative in preparation of medicine for treating or preventing cystic echinococcosis | |
| CN113350396B (en) | Preparation method of traditional Chinese medicine composition for resisting myocardial ischemia | |
| Rakebizadeh et al. | Supplemental effect of zinc oxide nanoparticles and mentha spicata butanol extract on blood glucose of diabetic wistar rats | |
| Shende et al. | Acute and Subacute Toxicity Studies of Ethanol, Chloroform extracts and Flower oil of Senecio edgeworthii hook plant | |
| AL-Taie | Hematological and histological Changes in mice Fed Aqueous Extract of Senna alexandrina | |
| CN113101308B (en) | Angelica gigas nakai extract and preparation method and application thereof | |
| Al-Juwary | Effects of pomegranate (Punica granatum L.) barks of root and stem (alcoholic extract) on the viability and fatty acids content of Echinococcus granulosus protoscolices in vitro study | |
| KR20010104497A (en) | Composition for B type Hepatitis and Cirrhosis of Liver Comprising Phellodendron amurense Rupr. cortex and Patrinia scabiosaefolia FISCH. Extract | |
| Kushwaha et al. | Hepatoprotective activity of ethanolic extract of Euphorbia royleana linn in carbon tetrachloride treated guinea pig | |
| KR20180085204A (en) | Composition for prevention and treatment of liver disease or obesity comprising Rheum undulatum Linne extract and Glycyrriza uralensis Fischer extract as active ingredients | |
| Kant et al. | Investigation on anti-diabetic and anti-hyperlipidemic activities of Blepharis edulis root extract in wistar albino rats | |
| Afriyie et al. | Acute Oral Toxicological Profile of Croton membranaceus Mull. Arg. Aqueous Stem Extract, a Herbal Treatment for Benign Prostate Hyperplasia, in Male Sprague–Dawley Rats | |
| Ivan et al. | Comparative Evaluation of the Anti-Inflammatory Properties of Methanol and Aqueous Crude Extracts of Apical leaves of Sida cuneifolia: An Ethnomedicinal Plant | |
| KR20050022944A (en) | Preventing or treating agent of blood vessel disease containing extract of Acanthopanax senticosus | |
| KR100452555B1 (en) | A composition comprising purified extract of wild ginseng having neuronal cell-protecting activity | |
| Shi et al. | Sedum sarmentosum Protects against Alcoholic Fatty Liver Disease in Mice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221123 Address after: Taiwan, Taipei, China Patentee after: Belks Biotechnology Co.,Ltd. Address before: Hsinchu County, Taiwan, China Patentee before: Industrial Technology Research Institute |